89bio Inc (ETNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 89bio Inc (ETNB) has a cash flow conversion efficiency ratio of -0.192x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-100.42 Million) by net assets ($521.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 89bio Inc (ETNB) balance sheet quality index to measure how much of total assets are equity-financed.
89bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how 89bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of 89bio Inc to assess how comfortably operating cash covers total debt obligations.
89bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 89bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rogers Corporation
NYSE:ROG
|
0.005x |
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
-0.009x |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
0.022x |
|
Business intelligence of Oriental Nations Corp Ltd
SHE:300166
|
0.000x |
|
Hilltop Holdings Inc
NYSE:HTH
|
0.123x |
|
Custom Truck One Source Inc
NYSE:CTOS
|
0.030x |
|
Mayora Indah Tbk
JK:MYOR
|
0.058x |
|
Schouw & Co.
CO:SCHO
|
0.002x |
Annual Cash Flow Conversion Efficiency for 89bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of 89bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see 89bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $400.79 Million | $-367.82 Million | -0.918x | -281.00% |
| 2023-12-31 | $536.31 Million | $-129.19 Million | -0.241x | +54.90% |
| 2022-12-31 | $151.83 Million | $-81.09 Million | -0.534x | +12.39% |
| 2021-12-31 | $125.96 Million | $-76.78 Million | -0.610x | -167.54% |
| 2020-12-31 | $202.96 Million | $-46.24 Million | -0.228x | +19.51% |
| 2019-12-31 | $89.94 Million | $-25.46 Million | -0.283x | -136.45% |
| 2018-12-31 | $-16.06 Million | $-12.47 Million | 0.777x | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more